Skip to main content

Decision Support

Our Decision Support services are designed to present patient results in the clearest way possible and to provide the information you need to take action in establishing treatment plans. Ranging from interpretation of results on each report to expert consultations and ongoing education, these services can help you make the most of comprehensive genomic profiling (CGP) in your practice.

Report Interpretation and Decision Support

Medical Case Consulting

Discuss patient results with our team of oncologists and pathologists. This robust on-call program is covered by physicians and Medical Science Liaisons (MSLs) within Foundation Medicine or by external oncologists who are subject matter experts and consultants for Foundation Medicine.

  • Inquiries can be escalated via phone, email, or through the “Ask an Expert” portal 

  • More than 100 inquiries per month are submitted and addressed successfully

  • Inquiries are handled within 24-48 hours in 95% of cases*

Streamlined Reports

Simplified test results provide information about genomic findings and biomarkers and their associated targeted therapies when available. We also provide information on clinically relevant alterations and available clinical trial options specific to each patient’s cancer. In addition to streamlined reports, other benefits include:

  • A single partner for all your testing services means consistent reporting for the comparison of results across the patient journey  

  • Reports for FoundationOne Liquid CDx include historic patient findings from earlier FoundationOne tests, which allow you to follow your patients’ genomic profiles across the duration of their diseases

Report Features

1

FDA-Approved Therapies

List of FDA-approved companion diagnostics, if available, to identify patients who may be eligible for treatment with associated therapies

2

Potential Resistance

This section appears when patients may be resistant to therapy based on their genomic profile

Illustration of a Foundation Medicine report

3

All Other Biomarkers

All other biomarkers and genomic signatures, including TMB and MSI†, without companion diagnostic claims

4

Professional Services

Interpretive content that can be used for patient management in accordance with professional guidelines in oncology

We’re Here to Help

Questions? Our Client Services team is on hand to help.

Contact Us

Additional Notes

*As of October 2019. 

On FoundationOne Liquid CDx, MSI status will be reported for samples determined to have high microsatellite instability. 

Important Safety Information

Select

FoundationOne Liquid CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration.  Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible.  For the complete label, including companion diagnostic indications and complete risk information, please visit  www.F1LCDxLabel.com.